Melanoma risk factors: Difference between revisions
Jump to navigation
Jump to search
YazanDaaboul (talk | contribs) No edit summary |
|||
| (8 intermediate revisions by 3 users not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{CMG}} {{AE}} {{YD}} | |||
{{CMG}} {{AE}} {{YD}}; {{SSK}} | |||
{{Melanoma}} | {{Melanoma}} | ||
==Overview== | ==Overview== | ||
The two most potent risk factors in the development of melanoma are light-colored skin and | The two most potent [[Risk factor|risk factors]] in the development of [[melanoma]] are light-colored skin and exposure to [[Ultraviolet|ultraviolet radiation]]. Other [[Risk factor|risk factors]] include old age, male gender, family history of [[melanoma]], personal history of [[Skin cancer|skin cancers]], [[immunodeficiency]], and certain [[Heredity|hereditary]] [[Disorder (medicine)|disorders]]. | ||
==Risk Factors== | ==Risk Factors== | ||
*The two most potent risk factors in the development of melanoma are '''light-colored skin''' and ''' | *The two most potent [[Risk factor|risk factors]] in the development of [[melanoma]] are '''light-colored skin''' and '''exposure to [[Ultraviolet|ultraviolet radiation]]'''.<ref name="pmid28077359">{{cite journal |vauthors=Ghiasvand R, Rueegg CS, Weiderpass E, Green AC, Lund E, Veierød MB |title=Indoor Tanning and Melanoma Risk: Long-Term Evidence From a Prospective Population-Based Cohort Study |journal=Am. J. Epidemiol. |volume=185 |issue=3 |pages=147–156 |date=February 2017 |pmid=28077359 |doi=10.1093/aje/kww148 |url=}}</ref><ref name="pmid18348450">{{cite journal |vauthors=Leiter U, Garbe C |title=Epidemiology of melanoma and nonmelanoma skin cancer--the role of sunlight |journal=Adv. Exp. Med. Biol. |volume=624 |issue= |pages=89–103 |date=2008 |pmid=18348450 |doi=10.1007/978-0-387-77574-6_8 |url=}}</ref> | ||
*Other Risk factors for the development of melanoma include: | *Other [[Risk factor|risk factors]] for the development of [[melanoma]] include: | ||
:*Old age | :*Old age<ref name="pmid30548854">{{cite journal |vauthors=Matas-Nadal C, Malvehy J, Ferreres JR, Boada A, Bodet D, Segura S, Salleras M, Azon A, Bel-Pla S, Bigata X, Campoy A, Curcó N, Dalmau J, Formigon M, Gonzalez A, Just M, Llistosella E, Nogues ME, Pedragosa R, Pujol JA, Sabat M, Smandia JA, Zaballos P, Puig S, Martí RM |title=Increasing incidence of lentigo maligna and lentigo maligna melanoma in Catalonia |journal=Int. J. Dermatol. |volume= |issue= |pages= |date=December 2018 |pmid=30548854 |doi=10.1111/ijd.14334 |url=}}</ref> | ||
:*Male gender | :*Male gender | ||
:*Family history of melanoma | :*Family history of [[melanoma]]<ref name="pmid10630172">{{cite journal |vauthors=Greene MH |title=The genetics of hereditary melanoma and nevi. 1998 update |journal=Cancer |volume=86 |issue=11 Suppl |pages=2464–77 |date=December 1999 |pmid=10630172 |doi= |url=}}</ref><ref name="pmid30060076">{{cite journal |vauthors=Gu F, Chen TH, Pfeiffer RM, Fargnoli MC, Calista D, Ghiorzo P, Peris K, Puig S, Menin C, De Nicolo A, Rodolfo M, Pellegrini C, Pastorino L, Evangelou E, Zhang T, Hua X, DellaValle CT, Timothy Bishop D, MacGregor S, Iles MI, Law MH, Cust A, Brown KM, Stratigos AJ, Nagore E, Chanock S, Shi J, Consortium MM, Consortium M, Landi MT |title=Combining common genetic variants and non-genetic risk factors to predict risk of cutaneous melanoma |journal=Hum. Mol. Genet. |volume=27 |issue=23 |pages=4145–4156 |date=December 2018 |pmid=30060076 |doi=10.1093/hmg/ddy282 |url=}}</ref><ref name="pmid30566178">{{cite journal |vauthors=Müller C, Wendt J, Rauscher S, Sunder-Plassmann R, Richtig E, Fae I, Fischer G, Okamoto I |title=Risk Factors of Subsequent Primary Melanomas in Austria |journal=JAMA Dermatol |volume= |issue= |pages= |date=December 2018 |pmid=30566178 |doi=10.1001/jamadermatol.2018.4645 |url=}}</ref> | ||
:*Multiple benign or atypical nevi | :*Multiple [[benign]] or atypical [[Nevus|nevi]]<ref name="pmid30566178">{{cite journal |vauthors=Müller C, Wendt J, Rauscher S, Sunder-Plassmann R, Richtig E, Fae I, Fischer G, Okamoto I |title=Risk Factors of Subsequent Primary Melanomas in Austria |journal=JAMA Dermatol |volume= |issue= |pages= |date=December 2018 |pmid=30566178 |doi=10.1001/jamadermatol.2018.4645 |url=}}</ref> | ||
:*Personal history of melanoma | :*Personal history of [[melanoma]] | ||
:*Administration of immunosuppressive therapy | :*Administration of [[immunosuppressive therapy]] | ||
:*Sun sensitivity | :*Sun sensitivity | ||
:*Therapeutic agents | :*Therapeutic agents such as: | ||
::* | ::*[[Psoralen]]<ref name="pmid29512683">{{cite journal |vauthors=Yin L, Pang G, Niu C, Habasi M, Dou J, Aisa HA |title=A novel psoralen derivative-MPFC enhances melanogenesis via activation of p38 MAPK and PKA signaling pathways in B16 cells |journal=Int. J. Mol. Med. |volume=41 |issue=6 |pages=3727–3735 |date=June 2018 |pmid=29512683 |doi=10.3892/ijmm.2018.3529 |url=}}</ref> | ||
::*Ultraviolet A light therapy | ::*[[PUVA|Ultraviolet A light therapy]]<ref name="pmid28077359">{{cite journal |vauthors=Ghiasvand R, Rueegg CS, Weiderpass E, Green AC, Lund E, Veierød MB |title=Indoor Tanning and Melanoma Risk: Long-Term Evidence From a Prospective Population-Based Cohort Study |journal=Am. J. Epidemiol. |volume=185 |issue=3 |pages=147–156 |date=February 2017 |pmid=28077359 |doi=10.1093/aje/kww148 |url=}}</ref> | ||
::*Neonatal blue light phototherapy | ::*[[Light therapy|Neonatal blue light phototherapy]] | ||
:* | :*Exposure to environmental chemicals such as: | ||
::*Polyvinyl chloride | ::*[[Polyvinyl chloride]] | ||
::*Heavy metals | ::*[[Heavy metals]] | ||
::*Pesticides | ::*[[Pesticides]] | ||
:*Hereditary diseases | :*[[Heredity|Hereditary]] [[Disease|diseases]] including: | ||
::*Giant congenital pigmented nevus syndrome | ::*Giant congenital pigmented nevus syndrome | ||
::*Melanocortin 1 receptor mutation | ::*[[Melanocortin 1 receptor]] [[mutation]]<ref name="pmid28676423">{{cite journal |vauthors=Herraiz C, Jiménez-Cervantes C, Sánchez-Laorden B, García-Borrón JC |title=Functional interplay between secreted ligands and receptors in melanoma |journal=Semin. Cell Dev. Biol. |volume=78 |issue= |pages=73–84 |date=June 2018 |pmid=28676423 |doi=10.1016/j.semcdb.2017.06.021 |url=}}</ref> | ||
::*Dysplastic nevus syndrome | ::*[[Dysplastic nevus syndrome]] | ||
::*Retinoblastoma | ::*[[Retinoblastoma]]<ref name="pmid27632029">{{cite journal |vauthors=Francis JH, Levin AM, Abramson DH |title=Update on Ophthalmic Oncology 2014: Retinoblastoma and Uveal Melanoma |journal=Asia Pac J Ophthalmol (Phila) |volume=5 |issue=5 |pages=368–82 |date=2016 |pmid=27632029 |doi=10.1097/APO.0000000000000213 |url=}}</ref> | ||
::*Xeroderma pigmentosum | ::*[[Xeroderma pigmentosum]]<ref name="pmid27785785">{{cite journal |vauthors=Naouali C, Jones M, Nabouli I, Jerbi M, Tounsi H, Ben Rekaya M, Ben Ahmed M, Bouhaouala B, Messaoud O, Khaled A, Zghal M, Abdelhak S, Boubaker S, Yacoub-Youssef H |title=Epidemiological trends and clinicopathological features of cutaneous melanoma in sporadic and xeroderma pigmentosum Tunisian patients |journal=Int. J. Dermatol. |volume=56 |issue=1 |pages=40–48 |date=January 2017 |pmid=27785785 |doi=10.1111/ijd.13448 |url=}}</ref> | ||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
[[Category:Up-To-Date]] | |||
[[Category:Oncology]] | |||
[[Category:Medicine]] | |||
[[Category:Dermatology]] | |||
[[Category:Surgery]] | |||
Latest revision as of 17:30, 3 January 2019
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Yazan Daaboul, M.D.; Serge Korjian M.D.
|
Melanoma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Melanoma risk factors On the Web |
|
American Roentgen Ray Society Images of Melanoma risk factors |
Overview
The two most potent risk factors in the development of melanoma are light-colored skin and exposure to ultraviolet radiation. Other risk factors include old age, male gender, family history of melanoma, personal history of skin cancers, immunodeficiency, and certain hereditary disorders.
Risk Factors
- The two most potent risk factors in the development of melanoma are light-colored skin and exposure to ultraviolet radiation.[1][2]
- Other risk factors for the development of melanoma include:
- Old age[3]
- Male gender
- Family history of melanoma[4][5][6]
- Multiple benign or atypical nevi[6]
- Personal history of melanoma
- Administration of immunosuppressive therapy
- Sun sensitivity
- Therapeutic agents such as:
- Exposure to environmental chemicals such as:
- Hereditary diseases including:
- Giant congenital pigmented nevus syndrome
- Melanocortin 1 receptor mutation[8]
- Dysplastic nevus syndrome
- Retinoblastoma[9]
- Xeroderma pigmentosum[10]
References
- ↑ 1.0 1.1 Ghiasvand R, Rueegg CS, Weiderpass E, Green AC, Lund E, Veierød MB (February 2017). "Indoor Tanning and Melanoma Risk: Long-Term Evidence From a Prospective Population-Based Cohort Study". Am. J. Epidemiol. 185 (3): 147–156. doi:10.1093/aje/kww148. PMID 28077359.
- ↑ Leiter U, Garbe C (2008). "Epidemiology of melanoma and nonmelanoma skin cancer--the role of sunlight". Adv. Exp. Med. Biol. 624: 89–103. doi:10.1007/978-0-387-77574-6_8. PMID 18348450.
- ↑ Matas-Nadal C, Malvehy J, Ferreres JR, Boada A, Bodet D, Segura S, Salleras M, Azon A, Bel-Pla S, Bigata X, Campoy A, Curcó N, Dalmau J, Formigon M, Gonzalez A, Just M, Llistosella E, Nogues ME, Pedragosa R, Pujol JA, Sabat M, Smandia JA, Zaballos P, Puig S, Martí RM (December 2018). "Increasing incidence of lentigo maligna and lentigo maligna melanoma in Catalonia". Int. J. Dermatol. doi:10.1111/ijd.14334. PMID 30548854.
- ↑ Greene MH (December 1999). "The genetics of hereditary melanoma and nevi. 1998 update". Cancer. 86 (11 Suppl): 2464–77. PMID 10630172.
- ↑ Gu F, Chen TH, Pfeiffer RM, Fargnoli MC, Calista D, Ghiorzo P, Peris K, Puig S, Menin C, De Nicolo A, Rodolfo M, Pellegrini C, Pastorino L, Evangelou E, Zhang T, Hua X, DellaValle CT, Timothy Bishop D, MacGregor S, Iles MI, Law MH, Cust A, Brown KM, Stratigos AJ, Nagore E, Chanock S, Shi J, Consortium MM, Consortium M, Landi MT (December 2018). "Combining common genetic variants and non-genetic risk factors to predict risk of cutaneous melanoma". Hum. Mol. Genet. 27 (23): 4145–4156. doi:10.1093/hmg/ddy282. PMID 30060076.
- ↑ 6.0 6.1 Müller C, Wendt J, Rauscher S, Sunder-Plassmann R, Richtig E, Fae I, Fischer G, Okamoto I (December 2018). "Risk Factors of Subsequent Primary Melanomas in Austria". JAMA Dermatol. doi:10.1001/jamadermatol.2018.4645. PMID 30566178.
- ↑ Yin L, Pang G, Niu C, Habasi M, Dou J, Aisa HA (June 2018). "A novel psoralen derivative-MPFC enhances melanogenesis via activation of p38 MAPK and PKA signaling pathways in B16 cells". Int. J. Mol. Med. 41 (6): 3727–3735. doi:10.3892/ijmm.2018.3529. PMID 29512683.
- ↑ Herraiz C, Jiménez-Cervantes C, Sánchez-Laorden B, García-Borrón JC (June 2018). "Functional interplay between secreted ligands and receptors in melanoma". Semin. Cell Dev. Biol. 78: 73–84. doi:10.1016/j.semcdb.2017.06.021. PMID 28676423.
- ↑ Francis JH, Levin AM, Abramson DH (2016). "Update on Ophthalmic Oncology 2014: Retinoblastoma and Uveal Melanoma". Asia Pac J Ophthalmol (Phila). 5 (5): 368–82. doi:10.1097/APO.0000000000000213. PMID 27632029.
- ↑ Naouali C, Jones M, Nabouli I, Jerbi M, Tounsi H, Ben Rekaya M, Ben Ahmed M, Bouhaouala B, Messaoud O, Khaled A, Zghal M, Abdelhak S, Boubaker S, Yacoub-Youssef H (January 2017). "Epidemiological trends and clinicopathological features of cutaneous melanoma in sporadic and xeroderma pigmentosum Tunisian patients". Int. J. Dermatol. 56 (1): 40–48. doi:10.1111/ijd.13448. PMID 27785785.